Phapros Turns from Loss to Profit of Rp27.44 Billion in 2025

Jakarta (ANTARA) - Pharmaceutical company PT Phapros Tbk (PEHA) recorded a net profit of Rp27.44 billion for the whole of 2025, a complete reversal from the net loss of Rp290.63 billion in 2024. The company’s net profit was supported by sales that grew 26.34% year-on-year to Rp940.88 billion throughout 2025. “This achievement is the result of five performance improvement strategies that have been consistently implemented by the company. Improvements in fundamental business operations have driven sales growth across all segments, successfully restoring the company’s sustainable profitability,” said Acting President Director of PEHA, Ida Rahmi Kurniasih, in an official statement in Jakarta on Wednesday. Ida stated that the company took strategic steps by carrying out business and marketing transformation as well as product portfolio optimisation, which also became important factors in driving sales growth. She continued that this achievement was due to strengthening discipline in sales and operations planning, improving the marketing team’s competencies, organising partnerships with distributors, product portfolio strategies, and strict cost efficiencies. “These strategies have proven able to reverse the company’s fundamental performance from loss to profit. Product portfolio organisation has successfully increased sales across all product segments, both OTC, OGB, and ethical,” said Ida. Sales growth occurred across all of the company’s product segments, including the over-the-counter (OTC) medicines segment, which grew 43.20% year-on-year, the branded generic medicines (OGB) segment, which grew 13.95% year-on-year, and the ethical segment, which grew 54.94% year-on-year. In line with that, the company managed to reduce operating expenses by 14.64% year-on-year to Rp406.43 billion in 2025, compared to Rp476.12 billion in 2024. Thus, the company was able to record significant net profit growth of 109% year-on-year in 2025. Ida continued that the cost restructuring strategy has proven successful in achieving production efficiencies, reflected in the 5.41% reduction in COGS, where the COGS to sales ratio in 2025 also fell significantly to 47.65% compared to 63.65% in 2024. Furthermore, another positive achievement is the successful reduction of liabilities to Rp959.70 billion in 2025, or a 7.45% year-on-year decrease compared to Rp1.04 trillion in 2024. The success in cutting liabilities has driven an increase in equity to Rp427.47 billion in 2025, or a 8.74% year-on-year growth compared to Rp393.12 billion in the previous year. “This equity growth also indicates that the company is increasingly valuable to its owners/shareholders,” she said.